Diversified Chinese pharma group making generics and innovative drugs and distributing medicines and devices nationwide.
Diversified Chinese pharma group making generics and innovative drugs and distributing medicines and devices nationwide.
Combines drug manufacturing, medical devices and hospitals with a pharmaceutical distribution business that earns thin margins on large volume. It holds a large minority stake in Sinopharm, China's biggest drug distributor. Its parent, the Fosun International investment conglomerate, controls it.
In one line: A Chinese cross between Sanofi and McKesson (mfg + distribution).
Moat: narrow (distribution, scale, regulatory licence). Broad national distribution network and manufacturing scale under the Fosun Group umbrella.
Headquarters: Shanghai, China · Founded: 1994 · Employees: 40,603
Size Shanghai Fosun Pharmaceutical (Group) (600196.SS) is a China Health Care company (Pharmaceuticals: Major) with a market value of $7.57B, the 309th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥20.82 on 18 Nov 2026.
Performance Over six months the shares fell 13.7%, against +4.4% for the median peer and -20.0% for the China market (cap-weighted) — 5th lowest of 21 in its peer set.
Growth Revenue grew 8.1% over the last twelve months (peer median +13.9%); the operating margin is 6.4% (peer median 16.4%).
Valuation It trades at 14.8× forward earnings against a peer median of 23.3× (4th cheapest of 15).
Price implies For today's price to make sense, revenue must grow about 3% a year for seven years (Req g). Recent delivered growth is +7%, so the hurdle is -4 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 1.1 points below its cost of capital (5.0% WACC).
Next results Next results expected around 29 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥42.7B | CN¥41.5B | CN¥40.9B | CN¥41.3B | CN¥43.8B |
| Revenue growth | — | +1% | -1% | -6% | — |
| Gross profit | CN¥23.5B | CN¥19.1B | CN¥18.1B | CN¥18.1B | CN¥19.5B |
| EBITDA | n/a | CN¥6.10B | CN¥5.78B | CN¥3.96B | CN¥5.57B |
| Net income | CN¥3.51B | CN¥3.37B | CN¥2.77B | CN¥2.39B | CN¥3.73B |
| Free cash flow | CN¥493M | CN¥1.56B | CN¥1.16B | -CN¥973M | -CN¥853M |
| Capital expenditure | CN¥5.55B | CN¥4.45B | CN¥4.41B | CN¥5.34B | CN¥5.89B |
| Total debt | CN¥41.5B | CN¥36.7B | CN¥36.7B | CN¥35.7B | CN¥31.1B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Shanghai Fosun Pharmaceutical (Group) 600196.SS | $7.57B | -14% | +8% | 6% | 14.8× | 2.9% |
| Shanghai Pharmaceuticals 601607.SS | $8.23B | 0% | +4% | 3% | 11.2× | -10.1% |
| Sbp 1177.HK | $12.2B | +5% | +15% | 30% | 17.5× | -5.7% |
| China Resources Pharmaceutical 3320.HK | $3.60B | -7% | +8% | 4% | 5.8× | -4.9% |
| Jiangsu Hengrui Pharmaceuticals 600276.SS | $45.7B | -13% | +6% | 27% | 33.4× | 13.4% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 600196.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -10.0% | +2.2% | 5th lowest of 21 |
| 6-month return | -13.7% | +4.4% | 5th lowest of 21 |
| Distance from 52-week high | -28.5% | -11.6% | 7th lowest of 21 |
| Revenue growth (TTM) | +8.1% | +13.9% | 8th lowest of 21 |
| Operating margin | 6.4% | 16.4% | 7th lowest of 20 |
| Forward P/E | 14.8× | 23.3× | 4th cheapest of 15 |
| Growth the price implies (Req g, 7 yrs) | 2.9% | 10.4% | 5th least demanding of 14 |
| Growth delivered (Del g) | +6.6% | +9.4% | 2nd lowest of 14 |
| Hurdle (Req g minus delivered) | -3.7 pp | -0.0 pp | 7th least demanding of 14 |
| ROIC minus cost of capital | -1.1 pp | +1.7 pp | 6th lowest of 19 |
| Net debt / EBITDA | 3.7× | -0.3× | 4th most indebted of 13 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Shanghai Fosun Pharmaceutical (Group) 600196.SS | China | $7.57B | -14% | +8% | 6% | 14.8× | 2.9% | +6.6% |
| Amneal Pharmaceuticals AMRX | United States | $7.62B | +79% | +9% | 16% | 19.2× | 17.2% | +8.7% |
| Grifols GRF.MC | Spain | $7.48B | +19% | +1% | 16% | 13.1× | 7.1% | +7.1% |
| Kiniksa Pharmaceuticals International KNSA | United States | $7.47B | +75% | +58% | 14% | 56.6× | 10.4% | +45.5% |
| Corcept Therapeutics CORT | United States | $7.42B | +15% | +30% | 12% | 15.3× | 23.9% | +16.6% |
| ONO Pharmaceutical 4528.T | Japan | $7.33B | -2% | -2% | 22% | 15.3× | -6.8% | +10.8% |
| Alkermes Public ALKS | United States | $7.87B | +27% | +15% | 5% | n/a | 32.5% | +7.3% |
| Asymchem Laboratories (Tianjin) 002821.SZ | China | $7.27B | +20% | +18% | 17% | 37.4× | n/a | n/a |
| ALK-abello A/S ALK-B.CO | Denmark | $7.94B | -8% | +16% | 26% | 34.8× | 7.3% | +12.6% |
| Glenmark Pharmaceuticals GLENMARK.NS | India | $7.98B | +10% | 0% | 17% | 33.1× | 27.3% | +9.4% |
| Cytokinetics CYTK | United States | $7.15B | -35% | +30% | -625% | n/a | n/a | n/a |
| ImmunityBio IBRX | United States | $7.13B | -17% | +121% | -150% | n/a | n/a | n/a |
| Bachem BANB.SW | Switzerland | $7.06B | 0% | +5% | 19% | 32.4× | n/a | n/a |
| Akeso 9926.HK | Hong Kong | $7.01B | -48% | +42% | -25% | n/a | n/a | n/a |
| Shanghai Pharmaceuticals 601607.SS | China | $8.23B | 0% | +4% | 3% | 11.2× | -10.1% | +8.1% |
| Rhythm Pharmaceuticals RYTM | United States | $8.25B | +31% | +61% | -67% | n/a | n/a | n/a |
| Protagonist Therapeutics PTGX | United States | $8.30B | +26% | +164% | 59% | 1,532.5× | 17.5% | +10.0% |
| Kyowa Kirin 4151.T | Japan | $8.43B | +9% | +10% | 24% | 16.4× | -4.7% | +9.3% |
| Praxis Precision Medicines PRAX | United States | $8.53B | -9% | -100% | n/a | n/a | n/a | n/a |
| Huadong Medicine 000963.SZ | China | $6.69B | -18% | +2% | 9% | 12.5× | -3.9% | +5.3% |
| Alkem Laboratories ALKEM.NS | India | $6.69B | -5% | +13% | 17% | 27.3× | 25.0% | +10.7% |